Verrica Pharmaceuticals Inc.

NasdaqGM:VRCA Stok Raporu

Piyasa değeri: US$65.3m

Verrica Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Verrica Pharmaceuticals CEO'su Ted White, Dec2017 tarihinde atandı, in görev süresi 6.92 yıldır. in toplam yıllık tazminatı $ 3.50M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.1% maaş ve 82.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.24% ine doğrudan sahiptir ve bu hisseler $ 158.30K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 6.5 yıldır.

Anahtar bilgiler

Ted White

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi17.1%
CEO görev süresi6.9yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi5.1yrs
Yönetim Kurulu ortalama görev süresi6.5yrs

Son yönetim güncellemeleri

Recent updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jul 21
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05
We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Vectoring Back In On Verrica Pharmaceuticals

Aug 31

Verrica Pharmaceuticals reports insider buying

Jul 06

Verrica Pharmaceuticals stock slides on proposed share offering

Jun 29

Verrica Pharmaceuticals Should Receive Second CRL Today

May 24

Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Mar 07
Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 06
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

Dec 17
Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA

May 28

Verrica Pharmaceuticals EPS beats by $0.32

May 07

Verrica Pharma refiles US application for lead candidate in infectious skin disease

Dec 23

CEO Tazminat Analizi

Ted White'un ücretlendirmesi Verrica Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$601k

-US$67m

Sep 30 2023n/an/a

-US$48m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$23m

Dec 31 2022US$2mUS$572k

-US$24m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$2mUS$550k

-US$35m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$2mUS$485k

-US$43m

Sep 30 2020n/an/a

-US$37m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$433k

-US$28m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$5mUS$400k

-US$21m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$24kUS$24k

-US$10m

Tazminat ve Piyasa: Ted 'nin toplam tazminatı ($USD 3.50M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.78K ).

Tazminat ve Kazançlar: Ted şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Ted White (59 yo)

6.9yrs

Görev süresi

US$3,504,647

Tazminat

Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ted White
President6.9yrsUS$3.50m0.24%
$ 158.3k
Christopher Hayes
Chief Legal Officer6.2yrsUS$2.56m0.15%
$ 100.6k
Gary Goldenberg
Chief Medical Officer4.3yrsUS$989.18k0.13%
$ 83.0k
Eugene Scavola
Executive Vice President of Technical Operations5.1yrsVeri yokVeri yok
Bradley Catalone
Head of Drug Development4.3yrsVeri yokVeri yok

5.1yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: VRCA 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ted White
President6.5yrsUS$3.50m0.24%
$ 158.3k
Mark Prygocki
Independent Director6.5yrsUS$119.19k0%
$ 0
Mark Lebwohl
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Lawrence F. Eichenfield
Independent Director4.3yrsUS$119.19k0%
$ 0
Sean Stalfort
Director8.9yrsVeri yok1.08%
$ 707.0k
Paul Manning
Chairman of the Board8.9yrsVeri yok31.75%
$ 20.7m
Steven Cohen
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Elaine Siegfried
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Anthony Mancini
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Janice Pelletier
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Robert Greenberg
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Diem Nguyen
Independent Director4.4yrsUS$99.19k0.00023%
$ 150.2

6.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VRCA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).